Verastem, Inc. (VSTM): R&D Expense
$114.60M
Year ended 2025-12-31
$140.22M
Trailing 12 months to 2026-06-30
+31.4%
3-year compound annual growth
+22.6%
5-year compound annual growth
+10.9%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $114.60M | +40.9% | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | $81.33M | +32.6% | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | $61.36M | +21.4% | 2026-03-04, From 2023-01-01 |
| 2022-12-31 | $50.56M | +28.5% | 2025-03-20, From 2022-01-01 |
| 2021-12-31 | $39.35M | -4.9% | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | $41.38M | -9.6% | 2023-03-14, From 2020-01-01 |
| 2019-12-31 | $45.78M | +4.9% | 2022-03-28, From 2019-01-01 |
| 2018-12-31 | $43.65M | -6.0% | 2021-03-18, From 2018-01-01 |
| 2017-12-31 | $46.42M | +134.7% | 2020-03-11, From 2017-01-01 |
| 2016-12-31 | $19.78M | -51.2% | 2019-03-12, From 2016-01-01 |
| 2015-12-31 | $40.56M | +14.4% | 2018-03-13, From 2015-01-01 |
| 2014-12-31 | $35.45M | +36.7% | 2017-03-23, From 2014-01-01 |
| 2013-12-31 | $25.93M | +19.4% | 2016-03-03, From 2013-01-01 |
| 2012-12-31 | $21.71M | +119.7% | 2015-03-10, From 2012-01-01 |
| 2011-12-31 | $9.88M | n/a | 2014-03-06, From 2011-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Verastem, Inc. (VSTM) | 2025-12-31 | $114.60M | +40.9% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $85.47M | -9.6% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $7.17M | -1.4% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $37.74M | +4.0% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $8.86M | -25.2% |
| Celularity Inc (CELU) | 2025-12-31 | $15.03M | -13.6% |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $604.3K | -35.3% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $142.27M | +13.5% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $672.7K | -50.6% |
Compare VSTM, FHTX, ZOMDF, CUE side by side · Screen every company in Pharmaceutical Preparations ↗